[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors].
D000230:Adenocarcinoma / Q000532:radiotherapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000528:radiation effects; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*
D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; D004999:Amifostine